Recent publications
- Clinical evaluation of zavegepant for the acute treatment of migraine May 30, 2025Zavegepant is the first intranasal calcitonin gene-related peptide receptor antagonist approved for the acute treatment of migraine and offers a new nonoral option for patients. This article reports the findings of a comprehensive literature review to assess zavegepant's safety and effectiveness. Evidence synthesis involved reporting findings from clinical trials and evaluating comparative effectiveness. This review […]Huiqiao Fan
- Re: Optimizing the Handling of Missing Data in the UNOS Database May 28, 2025No abstractWilliam L Baker
- Efficacy and harms associated with β-blockers for cardiotoxicity in cancer patients undergoing chemotherapy: a systematic review and meta-analysis May 21, 2025CONCLUSIONS: Prophylactic use of β-blockers for cardioprotection had little to no effect on all-cause mortality, LVEF or cardiac function outcomes in cancer patients undergoing anthracycline therapy.Jessica T Li
- An External Control Arm for the Oral Factor XIa Inhibitor Asundexian Phase 2 Trial in Atrial Fibrillation (PACIFIC-AF) Using Electronic Health Records May 16, 2025CONCLUSIONS: ECAs matching the PACIFIC-AF apixaban arm could be built from EHRs with concordant event rates for key trial endpoints. The ECA approach enabled the determination of event rates for treatment duration up to 2 years, thereby informing the asundexian pivotal phase 3 trial in AF.Tatsiana Vaitsiakhovich
- Improved oral anticancer medication (OAM) adherence/toxicity assessment documentation: A quality improvement initiative May 13, 2025IntroductionAdherence and toxicity symptoms ideally are monitored within 7-14 days after initiating oral anticancer medication (OAM). After implementing a formal OAM program at our institution, we found our adherence and toxicity monitoring was suboptimal and sought to improve our processes to reduce patient risk, using a formal quality improvement methodology.Patient and methodsAdult patients with a […]Lisa M Holle
- Comparative efficacy and safety of SGLT2 inhibitor class members in patients with heart failure and type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials May 5, 2025We conducted a systematic review with pairwise (PMA) and network meta-analyses (NMA) to evaluate sodium-glucose transport protein 2 inhibitor (SGLT2i) effects in patients with both heart failure (HF) and type 2 diabetes mellitus (T2DM). Five databases were searched up to April 15, 2025. Primary outcomes were all-cause mortality (ACM), cardiovascular death (CVD), all-cause hospitalization (ACH), […]Angela Y Su
- The association between diabetes and hypertension time course, their cumulative co-exposure, and post-coronary artery bypass graft outcomes May 3, 2025CONCLUSION: Our results highlight the significance of risk factor exposure duration in patient risk assessment. These insights could be valuable for enhancing existing risk assessment tools and developing tailored preventive strategies.Mana Jameie
- Sodium-glucose transporter-2 inhibitors: safety and efficacy in patients with peripheral artery disease April 29, 2025The objective of this review is to assess the safety and efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT-2is) in patients with peripheral arterial disease (PAD). A literature search of PubMed and EMBASE databases (through March 2025) was performed with MeSH words and phrases related to SGLT-2is AND PAD. Articles encompassing original research including results specifying safety […]Katelyn J Galli
- Common Bacterial Infections in Persons Who Inject Drugs April 23, 2025Opioid use in the United States has increased dramatically. Bacterial infections are common among persons who inject drugs (PWID), and there is a disparity in the care these individuals receive. As such, outcomes associated with these infections can be poor. Healthcare providers can address these disparities through optimal pharmacotherapy recommendations and assistance with changing approaches […]Michael P Lorenzo
- A case report on the safety and efficacy of aripiprazole for depression in Brugada syndrome April 14, 2025Brugada syndrome is a rare genetic cardiac abnormality that has been linked to aggravation of arrhythmias and sudden cardiac death through concomitant medication use, including psychotropic medications. This complicates the clinical team's approach to treatment of depression in patients with Brugada syndrome as many first-line psychotropic agents are recommended to be preferentially avoided. Aripiprazole, which […]Monica Fahmy
- Evolving Standards: An Examination of NAPLEX Blueprint Changes and Implications for the Academy April 5, 2025CONCLUSION: The 2025 NAPLEX blueprint resembles a shift toward clinical content in comparison to previous blueprints. Curricular outcomes related to solving problems; providing whole person care; and stewardship of medication systems for prescribing, order processing, dispensing, administration, and effects monitoring align with the new NAPLEX blueprint.Diana M Sobieraj
- Corticosteroid use beyond 1-year post heart transplantation is associated with worse outcomes: A contemporary analysis of the ISHLT registry March 27, 2025CONCLUSIONS: Steroid use beyond 1year post heart transplant was associated with significantly lower survival, and worsened morbidity among adult recipients. Whether this observation indicates steroid use is a marker of higher risk or worsens prognosis warrants prospective investigation.Abhishek Jaiswal
- Standard Instructions and Counseling for Naloxone Insufficient in the Era of Xylazine and Medetomidine Adulteration of Illicit Opioids March 20, 2025No abstractPriya Datta
- OLGA and OLGIM staging systems on the risk assessment of gastric cancer: a systematic review and meta‑analysis of prospective cohorts March 19, 2025CONCLUSION: Higher stages in OLGA and OLGIM systems are associated with a significantly increased risk of developing HGD and GC, validating these scoring systems for the assessment of GC risk and the design of endoscopic surveillance programs.Harold Benites-Goñi
- Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study March 19, 2025CONCLUSIONS: During 2012-2021, GLP-1 RA use steadily increased across multinational cohorts of patients with T2D and CKD, and persistence with treatment was high. GLP-1 use was independent of CKD severity.Manel Pladevall-Vila
- Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality March 10, 2025CONCLUSION: Delay in administering andexanet alfa due to hospital transfer may be associated with increased all-cause mortality.Huiqiao Fan
- Approaches for Embedding Structural Competency and Social Determinants of Health in Pharmacy Curricula March 3, 2025There is emerging scholarship related to teaching social determinants of health (SDOH) in pharmacy education; however, challenges remain for pharmacy educators due to a lack of formal consensus on which aspects of SDOH should be taught or evaluated. SDOH is often confused with similar, overlapping concepts such as cultural competence, cultural humility, Diversity, Equity, and […]Tyler Marie Kiles
- Renal Denervation Effects on Blood Pressure in Resistant and Uncontrolled Hypertension: A Meta-Analysis of Sham-Controlled Randomized Clinical Trials March 1, 2025CONCLUSION: RDN significantly reduced several SBP and DBP outcomes versus sham without significantly increasing complications. This makes RDN a potentially effective alternative to medications in URH.Hamidreza Soleimani
- The Burden of Hospital Illness Associated with Disseminated Versus Isolated Pulmonary Coccidioidomycosis in the United States February 25, 2025There are scarce data comparing inpatient mortality, length of stay (LOS) and all-cause hospital costs in disseminated coccidioidomycosis (DCM) vs. isolated pulmonary coccidioidomycosis (IPCM). We assessed the burden of hospital illness associated with DCM versus IPCM. This study was performed using National Inpatient Sample data from 2019 to 2021. DCM was defined as having a […]Craig I Coleman
- Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: an updated systematic review February 20, 2025CONCLUSION: The prevalence of buprenorphine dosing strategies that aim to omit POW has vastly increased over the past 4 years. While quality of evidence remains low, the increased quantity of publications and integration into health-system guidelines and protocols demonstrates the need for prospective, controlled studies. It is unknown how selection bias impacts current findings, further […]Kathleen K Adams